Cellebrite DI (NASDAQ:CLBT) CRO Marcus Jewell Sells 12,562 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,562 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $141,196.88. Following the sale, the executive owned 427,128 shares of the company’s stock, valued at $4,800,918.72. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Marcus Jewell also recently made the following trade(s):

• On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total transaction of $6,604.77.

Cellebrite DI Trading Up 4.0%

CLBT opened at $11.49 on Tuesday. The firm’s 50 day simple moving average is $14.24 and its two-hundred day simple moving average is $13.83. The company has a market capitalization of $2.87 billion, a PE ratio of 52.23, a PEG ratio of 1.53 and a beta of 1.18. Cellebrite DI Ltd. has a 1-year low of $9.58 and a 1-year high of $19.98.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Cellebrite DI by 16.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after purchasing an additional 24,881 shares during the period. Geode Capital Management LLC grew its holdings in Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after buying an additional 43,898 shares in the last quarter. Invesco Ltd. raised its position in shares of Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after buying an additional 209,473 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of Cellebrite DI in the second quarter worth $341,000. Finally, Marshall Wace LLP purchased a new position in shares of Cellebrite DI in the second quarter worth $4,472,000. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CLBT shares. DA Davidson lowered their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Needham & Company LLC decreased their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, August 13th. Lake Street Capital decreased their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.